These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15134483)

  • 1. Anti-HIV drug distribution to the central nervous system.
    Thomas SA
    Curr Pharm Des; 2004; 10(12):1313-24. PubMed ID: 15134483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.
    Varatharajan L; Thomas SA
    Antiviral Res; 2009 May; 82(2):A99-109. PubMed ID: 19176219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of CNS penetration of antiretroviral drugs.
    Wynn HE; Brundage RC; Fletcher CV
    CNS Drugs; 2002; 16(9):595-609. PubMed ID: 12153332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nevirapine uptake into the central nervous system of the Guinea pig: an in situ brain perfusion study.
    Gibbs JE; Gaffen Z; Thomas SA
    J Pharmacol Exp Ther; 2006 May; 317(2):746-51. PubMed ID: 16424147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms by which 2',3'-dideoxyinosine (ddI) crosses the guinea-pig CNS barriers; relevance to HIV therapy.
    Gibbs JE; Jayabalan P; Thomas SA
    J Neurochem; 2003 Feb; 84(4):725-34. PubMed ID: 12562517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
    Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
    AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.
    Letendre S; Marquie-Beck J; Capparelli E; Best B; Clifford D; Collier AC; Gelman BB; McArthur JC; McCutchan JA; Morgello S; Simpson D; Grant I; Ellis RJ;
    Arch Neurol; 2008 Jan; 65(1):65-70. PubMed ID: 18195140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choroid plexus controls brain availability of anti-HIV nucleoside analogs via pharmacologically inhibitable organic anion transporters.
    Strazielle N; Belin MF; Ghersi-Egea JF
    AIDS; 2003 Jul; 17(10):1473-85. PubMed ID: 12824785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig.
    Anthonypillai C; Sanderson RN; Gibbs JE; Thomas SA
    J Pharmacol Exp Ther; 2004 Mar; 308(3):912-20. PubMed ID: 14634041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients.
    Langford D; Marquie-Beck J; de Almeida S; Lazzaretto D; Letendre S; Grant I; McCutchan JA; Masliah E; Ellis RJ
    J Neurovirol; 2006 Apr; 12(2):100-7. PubMed ID: 16798671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of cerebrospinal fluid: potential for the study of HIV-1 infection of the central nervous system.
    Cinque P; Bestetti A; Morelli P; Presi S
    J Neurovirol; 2000 May; 6 Suppl 1():S95-S102. PubMed ID: 10871772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system.
    Sawchuk RJ; Yang Z
    Adv Drug Deliv Rev; 1999 Oct; 39(1-3):5-31. PubMed ID: 10837765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 reverse transcriptase inhibitors.
    El Safadi Y; Vivet-Boudou V; Marquet R
    Appl Microbiol Biotechnol; 2007 Jun; 75(4):723-37. PubMed ID: 17370068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
    Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
    Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral drug concentrations in semen of HIV-1 infected men.
    Taylor S; Pereira AS
    Sex Transm Infect; 2001 Feb; 77(1):4-11. PubMed ID: 11158684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.